Insight: prolonged vaginal bleeding during central precocious puberty therapy with a long-acting gonadotropin-releasing hormone agonist: a proposed mechanism and management plan

J Pediatr Adolesc Gynecol. 2011 Dec;24(6):365-7. doi: 10.1016/j.jpag.2011.06.007. Epub 2011 Aug 27.

Abstract

We have previously described our data collected after administration of gonadotropin releasing hormone-agonist (GnRH-a) to delay sexual maturation, in premenarchal girls suffering from idiopathic central precocious puberty.(1) We have explained the recurrent episodes of bleeding due to discontinuation of the estrogen support of the proliferative and stable endometrium. The recognition in recent years of the extra-pituitary functions of GnRH-a, the ability of GnRH to stimulate prostaglandin production and the known role of prostaglandins in irregular vaginal bleeding prompted us to seek alternative explanations to our data. We suggest considering a potential clinical use of combination therapies of GnRH agonists and prostanoid receptor antagonists to treat central precocious puberty.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cyclooxygenase 2 / metabolism
  • Dinoprostone / metabolism
  • Female
  • Gonadotropin-Releasing Hormone / agonists*
  • Gonadotropin-Releasing Hormone / metabolism
  • Humans
  • Puberty, Precocious / drug therapy*
  • Receptors, Prostaglandin / antagonists & inhibitors*
  • Signal Transduction
  • Uterine Hemorrhage / chemically induced
  • Uterine Hemorrhage / drug therapy*

Substances

  • Receptors, Prostaglandin
  • Gonadotropin-Releasing Hormone
  • Cyclooxygenase 2
  • Dinoprostone